TEST:

Canhelp-Origin® Assay

This study demonstrates the significant impact of a 90-gene expression assay on diagnosis and potential treatment selection for difficult-to-diagnose patients, highlighting its clinical value as a standardized molecular approach to streamline further diagnostic testing for patients with metastatic cancer of unclear or unknown origin. Further prospective study is required to assess whether employing molecular diagnostic classifiers enhances clinical outcomes in these patients.

This study demonstrates that the 90-gene expression assay has diagnostic implications for patients with cancer of unknown or unclear primary. This affirms its clinical utility as a standard diagnostic approach in the diagnosis and management of these patients, facilitating the formulation of more precise treatment strategies and ultimately enhancing prognosis.

We recommend a CUP diagnostic strategy involving the use of targeted antibody panels as per histological findings that is potentially applicable in clinical practice. The markers TRPS1, INSM1, and P16 expression, as well as HPV and EBER testing are particularly valuable in this aspect. Molecular testing is also predictive of survival rates.

"Chinese molecular diagnostics company Canhelp Genomics has received approval from China's National Medical Products Administration (NMPA) for its Canhelp-Origin pan-cancer test and companion analysis software...A PCR-based tissue-of-origin assay, the Canhelp-Origin Test can measure the gene expression pattern of 90 specific markers of tissue samples and classifies 21 major tumor types that cover more than 95 percent of solid tumors by incidence, the company said."